IJDVL Home  

[Download PDF]  
Year : 2008  |  Volume : 74  |  Issue : 3  |  Page : 273-274

Authors' reply

Viroj Wiwanitkit 
 Department of Clinical Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Correspondence Address:
Viroj Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok 10160

How to cite this article:
Wiwanitkit V. Authors' reply.Indian J Dermatol Venereol Leprol 2008;74:273-274

How to cite this URL:
Wiwanitkit V. Authors' reply. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2019 Nov 15 ];74:273-274
Available from: http://www.ijdvl.com/text.asp?2008/74/3/273/41387

Full Text


The accuracy of prediction of relative or absolute ligand-binding affinities is challenging in both theoretical and practical aspects. [1] Receptor-ligand docking simulation for membrane proteins is widely used in structural bioinformatics. [2] Ligand-binding site prediction is useful in antagonist-type drug search. [3],[4] Ligand-binding site prediction for ErbB2, a membrane protein, was discussed in a previous report. [5]

The generation of highly effective signalling inhibitors targeting members of the ErbB family of receptor tyrosine kinases, EGFR and ErbB-2 has been discussed for a few years. [6] Of interest, Rambukkana et al. mentioned that during Microbacterium leprae -induced demyelination, Schwann cells proliferated significantly and generated a more nonmyelinated phenotype, thereby securing the intracellular niche for M. Leprae. [7] Recently, Tapinos et al. provided evidence that M. leprae -induced demyelination was a result of direct bacterial ligation to and activation of ErbB2 receptor tyrosine kinase (RTK) without ErbB2-ErbB3 heterodimerization, a previously unknown mechanism that bypasses the neuregulin-ErbB3-mediated ErbB2 phosphorylation. [8] Therefore, it might be concluded that an ErbB2 antagonist could be useful in leprosy therapy, especially as a dedifferentiation signal in leprosy. [9]


1Huang N, Jacobson MP. Physics-based methods for studying protein-ligand interactions. Curr Opin Drug Discov Dev 2007;10:325-31.
2Hirokawa T. Receptor-ligand docking simulation for membrane proteins. Yakugaku Zasshi 2007;127:123-31.
3Mattos C, Ringe D. Locating and characterizing binding sites on proteins. Nat Biotechnol 1996;14:595-9.
4Singh J, Deng Z, Narale G, Chuaqui C. Structural interaction fingerprints: A new approach to organizing, mining, analyzing and designing protein-small molecule complexes. Chem Biol Drug Des 2006;67:5-12.
5Wiwanitkit V. Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy. Indian J Dermatol Venereol Leprol 2008;74:32-4.
6Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Top Med Chem 2006;6:435-60.
7Rambukkana A, Zanazzi G, Tapinos N, Salzer JL. Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells. Science 2002;296:927-31.
8Tapinos N, Ohnishi M, Rambukkana A. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med 2006;12:961-6.
9Noon LA, Lloyd AC. Treating leprosy: An Erb-al remedy? Trends Pharmacol Sci 2007;28:103-5.


Friday, November 15, 2019
 Site Map | Home | Contact Us | Feedback | Copyright and disclaimer